A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of S-588410 as adjuvant therapy after curative resection in patients with esophageal cancer
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2017
At a glance
- Drugs S-288310/S-488310 (Primary)
- Indications Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Sponsors OncoTherapy Science; Shionogi
- 27 Mar 2015 Status changed from planning to recruiting as per University Hospital Medical Information Network - Japan .
- 25 Feb 2015 New trial record
- 23 Feb 2015 Shionogi will conduct this phase III trial in collaboration with OncoTherapy, according to an OncoTherapy media release.